IZB Start-up mk2
Mk2 Biotechnologies GmbH was founded in 2020 and is located in the Innovation and Start-up Centre IZB in Planegg-Martinsried.
ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 194 entries already.
Mk2 Biotechnologies GmbH was founded in 2020 and is located in the Innovation and Start-up Centre IZB in Planegg-Martinsried.
2023 was another particularly tumultuous year for life sciences and, although the lingering effects of the last year are unlikely to change dramatically, the stabilisation of interest rates (off 16-year highs) and emerging direction of travel (market data points) tilt our bias to positive for the new year.
In November 2023, Enhanc3D Genomics appointed Dr Hazel Jones as interim CEO and COO. Now she has taken over the Position of CEO officially.
Over the past few years, the Frankfurt Institute of Clinical Cancer Research (IKF) has successfully conducted over 90 clinical studies. Each year, it enrolls approximately 1,500 patients in these trials. European Biotechnology spoke with the founder and director Prof. Dr med. Salah-Eddin Al-Batran.
The 2023 State of the Union speech saw biotechnology rise as a priority for the European Union. It has been designated as a critical technology for Europe’s economic security. In March 2024, the European Commission presented its biotechnology and biomanufacturing strategy with a clear leadership ambition for Europe’s biotech industries. The Letta Report on the future of the Single Market, published April 2024, proposed a fifth freedom on research and innovation which would directly benefit biotech.
Dublin-based ERS Genomics Ltd appointed John E Milad as CEO in the middle of May. He took over from Erik Rhodes, CEO for the last eight years.
Dale Levitzke has been appointed as CEO of Sphere Fluidics. He follows CEO and co-founder Dr Frank F. Craig, who announced his retirement after 14 years leading the company.
Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors. Furthermore, using them together with a powerful bioprocess controller like the BioFlo® 320 enables precise cell culture parameter control and seamless process transition to up to 40 L of working volume.
Global contract research organization honored as top outsourcing partner, earning high marks in several categories from Industry Standard Research.
Oslo-based Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance.